Total trials
117
Active
74
Phase 3
3
Total enrollment
3,657,057
Pipeline matrix
Showing 16 of 16 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Apixaban 2.5 milligram Oral | — | — | — | — | — | 1 | |
| 5U/0,1 ml Botulinum toxin A | — | — | — | — | — | 1 | |
| 10U/0,1 ml Botulinum toxin A | — | — | — | — | — | 1 | |
| Dapagliflozin 10 mg once daily | — | — | — | — | — | 1 | |
| Lithium | — | — | — | — | — | 1 | |
| Darolutamide | — | — | — | — | — | 1 | |
| Roxadustat | — | — | — | — | — | 1 | |
| Darbepoietin Alfa | — | — | — | — | — | 1 | |
| IEM-EP | — | — | — | — | — | 1 | |
| monoclonal CD-20 antibodies | — | — | — | — | — | 1 | |
| No Drug | — | — | — | — | — | 1 | |
| Other treatment | — | — | — | — | — | 1 | |
| Induced hypertension with norepinephrine | — | — | — | — | — | 1 | |
| Endoluminal Spasmolysis | — | — | — | — | — | 1 | |
| High Flow Oxygen | — | — | — | — | — | 1 | |
| Oxygen | — | — | — | — | — | 1 |
Next readouts
- 2026-12-01
- 2027-01-01
- 2027-06
- 2027-10
- 2027-12
- 2027-12-31
- 2028-03-09
- 2029-12-31
- 2030-08-31
- 2030-12-31
Top conditions
- Depression3
- Clubfoot3
- Multiple Sclerosis3
- Endometriosis3
- Heart Failure3
- Physical Inactivity2
- Bipolar Disorder2
- Anxiety2
Frequently asked questions about Region Stockholm
- How many clinical trials does Region Stockholm have on ClinicalTrials.gov?
- Region Stockholm is listed as the lead sponsor on 117 clinical trials in ClinicalTrials.gov, 74 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Region Stockholm's trials are in Phase 3?
- 3 of Region Stockholm's trials are in Phase 3, spread across 16 active drug programs.
- What therapeutic areas does Region Stockholm focus on?
- Region Stockholm's most-studied conditions on ClinicalTrials.gov are Depression, Clubfoot, Multiple Sclerosis, Endometriosis, Heart Failure.
- When are Region Stockholm's next clinical trial readouts?
- Region Stockholm has 10 upcoming primary-completion readouts tracked here; the soonest is “Botulinumtoxin A as a Treatment for Myalgia and Myofacial Pain in Patient With Temporomandibulardisorders”, expected around 2026-12-01.